Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency

被引:18
|
作者
Terrell, Deirdra R.
Motto, David G.
Hovinga, Johanna A. Kremer
Laemmle, Bernhard
George, James N.
Vesely, Sara K. [1 ]
机构
[1] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Coll Publ Hlth, Oklahoma City, OK 73126 USA
基金
瑞士国家科学基金会;
关键词
VON-WILLEBRAND-FACTOR; HEMOLYTIC-UREMIC SYNDROME; FACTOR-CLEAVING PROTEASE; ABO; PLASMA; DISEASE; PROTEOLYSIS; FRETS-VWF73; PHENOTYPE; SURVIVAL;
D O I
10.1111/j.1537-2995.2011.03125.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: It has been postulated that blood group O subjects may be partially protected against thrombotic thrombocytopenic purpura (TTP) because they have lower plasma levels of von Willebrand factor. STUDY DESIGN AND METHODS: The Oklahoma TTP Registry enrolled 301 consecutive patients from November 13, 1995 (when systematic ADAMTS13 measurements began), through 2009; 281 (93%) patients had ADAMTS13 measurements. Patients were designated as having severe ADAMTS13 deficiency when the activity measurement by either method was less than 10%. ABO blood group was determined in all 281 patients. The observed frequency of blood group O was compared to the expected frequency. The association between severe ADAMTS13 deficiency and blood group, race, sex, and age were analyzed by logistic regression. RESULTS: The frequency of blood group O was unexpectedly and significantly greater than the race-ethnicity-adjusted expected frequency in 65 patients with severe ADAMTS13 deficiency (60.0% vs. 47.4%, p = 0.042) but not in 216 patients without severe ADAMTS13 deficiency (44.9% vs. 46.5%, p = 0.639). Blood group O and race-ethnicity were independently associated with severe ADAMTS13 deficiency among patients with TTP. The probability for severe ADAMTS13 deficiency was 45.8% with O and 32.1% with non-O blood groups for black patients and 24.1% with O and 15.1% with non-O blood groups for white patients. CONCLUSION: Among patients with TTP and severe ADAMTS13 deficiency the relative frequency of patients with blood group O was greater than expected, suggesting that blood group O may be a risk factor for TTP associated with severe ADAMTS13 deficiency.
引用
收藏
页码:2237 / 2243
页数:7
相关论文
共 50 条
  • [21] Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura
    Bendapudi, Pavan K.
    Foy, Brody H.
    Mueller, Sarah B.
    Liu, Jun
    Feingold, Louis M.
    Burke, Kristen E.
    Cruz, Wendy
    Chen, Maria Y.
    Lau, Emily S.
    Goldberg, Rachel L.
    Tatake, Ishan
    Wilkinson, Shelby C.
    Carney, Brian J.
    Stone, James R.
    Park, Doyun
    Avelino, Alzira R.
    Hassan, Sajjad
    Andrzejewski, Chester
    Ruby, Kristen N.
    Friedman, Kenneth D.
    Brunker, Patricia A. R.
    Leaf, Rebecca K.
    Higgins, John
    Dzik, Walter H.
    Stefely, Jonathan A.
    Makar, Robert S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (18): : 1690 - 1698
  • [22] Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura
    Wendt, Ralph
    Voelker, Linus A.
    Brinkkoetter, Paul T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04): : 382 - 384
  • [23] Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura
    Lorenz, Judith
    ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE, 2024, 228 (05): : 410 - 411
  • [24] ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy
    Raman, Rachna
    Yang, Shangbin
    Wu, Haifeng M.
    Cataland, Spero R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (02) : 277 - 278
  • [25] Thrombotic Thrombocytopenic Purpura: Relationship of Infection and ADAMTS13
    Watanaboonyongcharoen, P.
    Brecher, M. E.
    Schultz, E. F.
    Hay, S. N.
    Park, Y. A.
    TRANSFUSION, 2012, 52 : 126A - 127A
  • [26] Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura
    Asmis, Lars M. M.
    Serra, Andreas
    Krafft, Alexander
    Licht, Abraham
    Leisinger, Elke
    Henschkowski-Serra, Jana
    Ganter, Michael T. T.
    Hauptmann, Steffen
    Tinguely, Marianne
    Hovinga, Johanna A. Kremer A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (25): : 2356 - 2361
  • [27] Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura
    Cataland, Spero R.
    Wu, Haifeng M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (04) : 437 - 444
  • [28] Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura
    Scully, Marie
    Antun, Ana
    Cataland, Spero R.
    Coppo, Paul
    Dossier, Claire
    Biebuyck, Nathalie
    Hassenpflug, Wolf-Achim
    Kentouche, Karim
    Knoebl, Paul
    Kremer Hovinga, Johanna A.
    Lopez-Fernandez, M. Fernanda
    Matsumoto, Masanori
    Ortel, Thomas L.
    Windyga, Jerzy
    Bhattacharya, Indranil
    Cronin, Michael
    Li, Hong
    Mellgard, Bjorn
    Patel, Munjal
    Patwari, Parth
    Xiao, Shan
    Zhang, Pinghai
    Wang, Linda T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (17): : 1584 - 1596
  • [29] Diagnostic Challenges in a Case of Immune-Mediated Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency
    Escoto-Pineda, Karel
    Alas-Pineda, Cesar
    Pavon-Varela, Dennis Javier
    Cortes, David
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [30] Seasonal distribution of severe ADAMTS13 deficient idiopathic thrombotic thrombocytopenic purpura
    Raval, Jay S.
    Harm, Sarah K.
    Rollins-Raval, Marian A.
    Kiss, Joseph E.
    JOURNAL OF CLINICAL APHERESIS, 2014, 29 (02) : 113 - 119